Franklin Resources’s Aimmune Therapeutics AIMT Stock Holding History

Franklin Resources’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-395,300	Closed	-$8.23M	–	1584
2019 Q2	$8.23M	Hold	395,300	–	–	﹤0.01%	938
2019 Q1	$8.84M	Hold	395,300	–	–	﹤0.01%	912
2018 Q4	$9.46M	Sell	395,300 -95,600	-19%	-$2.47M	0.01%	877
2018 Q3	$13.4M	Sell	490,900 -34,000	-6%	-$962K	0.01%	876
2018 Q2	$14.1M	Hold	524,900	–	–	0.01%	861
2018 Q1	$16.7M	Buy	524,900 +30,400	+6%	+$1.07M	0.01%	827
2017 Q4	$18.7M	Buy	+494,500	New	+$16M	0.01%	807
2015 Q4	–	Sell	-68,413	Closed	-$1.73M	–	1616
2015 Q3	$1.73M	Buy	+68,413	New	+$1.6M	﹤0.01%	1314

Other funds holding AIMT

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources's AIMT Position: Q3 2019 in Review

Franklin Resources sold out of Aimmune Therapeutics (AIMT) in Q3 2019, closing a stake of 395,300 shares — an estimated $8.23M sold.

Franklin Resources first reported a position in AIMT in Q3 2015 and held it in 8 quarters. The position peaked at $18.7M in Q4 2017. 146 funds tracked by Wall St. Rank hold AIMT as of Q3 2019.

Franklin Resources reported no remaining Aimmune Therapeutics position as of Q3 2019 after selling out during the quarter.
Franklin Resources sold 395,300 Aimmune Therapeutics shares in Q3 2019, an estimated $8.23M.
Franklin Resources first reported a position in Aimmune Therapeutics in Q3 2015 and held it in 8 quarters.
Franklin Resources's Aimmune Therapeutics position peaked at $18.7M in Q4 2017.
146 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q3 2019.

Based on Franklin Resources's 13F filing for Q3 2019, filed 14 Nov 2019.